Payers: Navigating the Economics that Determine Access

Entrepreneurs entering the medical technology space often begin with an idea, an elegant mechanism, a clever algorithm, or a new way to diagnose or treat disease. But innovation alone doesn’t guarantee impact. A device only becomes meaningful when it aligns with the needs, motivations, and constraints of the people who will use it or be affected by it.

This five-part series is designed for founders and early-stage teams who want to expand their understanding of their market landscape through the lens of the Five Ps: Patients, Physicians (clinicians), Providers (facilities and organizations), Payers (insurance companies), and Policy Makers. Each article explores one stakeholder group, discussing the dynamics that shape their decisions and the unmet needs that should guide your product development.

The fourth article in the series­—a look at Payers—outlines how insurers evaluate medical technologies through evidence, cost-effectiveness, and reimbursement pathways.

The Insurer’s Role

Payers, public and private insurers, play a decisive role in determining whether your medical technology reaches patients. Their decisions shape coverage, reimbursement, and ultimately the commercial viability of your product. Yet, for many entrepreneurs, the world of payers feels opaque, technical, and intimidating. Understanding their motivations is essential.

The first step is recognizing that payer landscapes vary dramatically by geography. In countries with universal healthcare systems, coverage tends to be broad and consistent. In mixed systems, essential devices are typically covered by public insurance, while private insurance offers faster access or additional options. In the United States, the landscape is fragmented: Medicare and Medicaid operate alongside a vast array of private insurers, each with its own policies, formularies, and reimbursement structures.

From product launches to M&A and manufacturing trends, the ODT Now delivers the orthopedic device news you need weekly. Subscribe here!

Payers evaluate technologies through a financial lens tied to clinical benefits. They consider the cost of predicate products, the total cost of care, and the evidence supporting clinical utility. A device that reduces hospitalizations, shortens recovery times, or prevents complications may be highly attractive, even if its upfront cost is higher, because it lowers long-term expenditures. This is why preventive screenings like mammograms and colonoscopies are widely covered in the U.S.: early detection reduces the cost of treating advanced disease.

Understanding the way payment works is equally important. Depending on the product, you might need to navigate J-codes, CPT codes, HCPCS classifications, or formulary placement. These codes determine how providers bill for your device and how payers reimburse them. Securing the right code, or demonstrating that your product fits within an existing one, can have a significant impact on its adoption.

The unmet needs of payers often revolve around clarity and evidence. They want data that demonstrates not only clinical benefit but economic value. They want predictable outcomes, reduced variability, and technologies that align with broader trends in value-based care. They also want transparency: clear pricing, clear pathways, and clear justification for why your product deserves coverage.

For entrepreneurs, the key is to engage early. Waiting until your product is ready to launch to think about reimbursement will only set you up for potential failure. Build your evidence strategy early with payer expectations in mind. When you understand their priorities, you can position your technology not just as a clinical innovation, but as a financial one.

A Word from Webeck

Payers don’t buy innovation: they buy value, predictability, and evidence that a technology lowers total cost of care. A strong reimbursement strategy isn’t something you bolt on at the end; it’s something you build alongside the product itself. The companies that win are the ones that speak the language of outcomes and economics with equal fluency.

References

1. tinyurl.com/odt260781
2. tinyurl.com/odt260782

More from this author—Providers: Understanding the Organizations That Shape Adoption

Ilsa Webeck has more than 30 years of experience assessing commercial and market viability in the medtech space. At Simbex, a design, development, and commercialization firm, she works with companies of all sizes in support of the commercialization pathway, performing primary and secondary research to uncover unmet needs, establishing value propositions, and supporting development of regulatory, reimbursement, and quality strategies. Prior to Simbex, Webeck founded MedTech Strategies, where she worked with a wide range of medtech organizations focused on assessing commercial fit and establishing a path to commercial success. Her previous experiences include group product director at J&J’s DePuy Spine, leading the strategic marketing efforts and upstream marketing team, and associate director for global commercial strategy in the MS Franchise at Biogen Idec. For more information, visit www.simbex.com.